Published in Int J Mol Sci on September 25, 2014
The protective effect of Rhizoma Dioscoreae extract against alveolar bone loss in ovariectomized rats via regulating Wnt and p38 MAPK signaling. Nutrients (2014) 0.76
Ursolic acid derivative ameliorates streptozotocin-induced diabestic bone deleterious effects in mice. Int J Clin Exp Pathol (2015) 0.75
Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology. J Anal Methods Chem (2016) 0.75
Antibiotic administration alleviates the aggravating effect of orthodontic force on ligature-induced experimental periodontitis bone loss in mice. J Periodontal Res (2017) 0.75
Anti- trachea inflammatory effects of diosgenin from Dioscorea nipponica through interactions with glucocorticoid receptor α. J Int Med Res (2016) 0.75
Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro. Bone Rep (2016) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med (2006) 7.46
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology (1998) 4.29
Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2007) 2.55
The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone (1999) 2.16
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet (2007) 2.04
The laboratory rat as an animal model for osteoporosis research. Comp Med (2008) 1.97
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet (2008) 1.41
Skeletal alterations in ovariectomized rats. Calcif Tissue Int (1985) 1.38
Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr (2009) 1.37
Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol (2006) 1.27
A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer (2006) 1.23
Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res (2003) 1.20
Antioxidative and hypolipidemic effects of diosgenin, a steroidal saponin of yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci Biotechnol Biochem (2007) 1.07
Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs (2000) 1.03
Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop (2013) 1.02
Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues. Mol Nutr Food Res (2010) 0.99
The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model. Biomed Sci Instrum (2001) 0.97
Expression of RANKL/OPG during bone remodeling in vivo. Biochem Biophys Res Commun (2011) 0.95
Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res (2002) 0.95
Diosgenin--a growth stimulator of mammary gland of ovariectomized mouse. Indian J Exp Biol (1992) 0.93
Variation in the short-term changes in bone cell activity in three regions of the distal femur immediately following ovariectomy. J Bone Miner Res (1998) 0.93
Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol (2000) 0.92
A Japanese herbal medicine, Chujo-to, has a beneficial effect on osteoporosis in rats. Phytother Res (1999) 0.89
National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. Menopause Int (2011) 0.89
Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo. Phytomedicine (2010) 0.89
Protective effects of diosgenin in the hyperlipidemic rat model and in human vascular endothelial cells against hydrogen peroxide-induced apoptosis. Chem Biol Interact (2010) 0.88
Evaluation of the pathogenesis of skeletal changes in ovariectomized rats. Endocrinology (1984) 0.88
Final report of the amended safety assessment of Dioscorea Villosa (Wild Yam) root extract. Int J Toxicol (2004) 0.87
Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. J Bone Miner Res (2004) 0.84
Modulatory effects of diosgenin on attenuating the key enzymes activities of carbohydrate metabolism and glycogen content in streptozotocin-induced diabetic rats. Can J Diabetes (2014) 0.84
Microdetermination of diosgenin from fenugreek (Trigonella foenum-graecum) seeds. J Agric Food Chem (2000) 0.83
The effects of sustained delivery of diosgenin on the adrenal gland of female rats. Biomed Sci Instrum (2003) 0.80
Diosgenin attenuates vascular calcification in chronic renal failure rats. Mol Cell Biochem (2013) 0.80
Structural changes in the kidney associated with ovariectomy and diosgenin replacement therapy in adult female rats. Biomed Sci Instrum (2003) 0.79
Steroids, XXVII. Synthesis of allopregnane-3beta, 11beta, 17alpha-, 20beta, 21-pentol from cortisone and diosgenin. J Biol Chem (1952) 0.79
The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats. Biol Pharm Bull (2012) 0.78
Structural requirement of spirostanol glycosides for rat uterine contractility and mode of their synergism. J Pharm Pharmacol (2010) 0.78
Effects of diosgenin on myometrial matrix metalloproteinase-2 and -9 activity and expression in ovariectomized rats. Int J Biol Sci (2011) 0.78
Diosgenin does not express estrogenic activity: a uterotrophic assay. Can J Physiol Pharmacol (2014) 0.76
Effects of chronic treatment with diosgenin on bone loss in a D-galactose-induced aging rat model. Chin J Physiol (2014) 0.76
The prevention of osteoporotic progression by means of steroid loaded TCPL drug delivery systems. Biomed Sci Instrum (2001) 0.76
The protective effect of Rhizoma Dioscoreae extract against alveolar bone loss in ovariectomized rats via regulating Wnt and p38 MAPK signaling. Nutrients (2014) 0.76
Rhizoma Dioscoreae extract protects against alveolar bone loss in ovariectomized rats via microRNAs regulation. Nutrients (2015) 0.75
Effect of Curcumin on the Diversity of Gut Microbiota in Ovariectomized Rats. Nutrients (2017) 0.75